MedTrace Logo

ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)

NCT02931175 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-12-17

No results posted yet for this study

Summary

The study aims to evaluate the potential role of ACTH gel in the management of non-infectious uveitis.

Conditions

  • Uveitis

Interventions

DRUG

ACTH gel

Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.

Sponsors & Collaborators

  • Mallinckrodt

    collaborator INDUSTRY

  • Quan Dong Nguyen

    lead OTHER

Principal Investigators

  • Quan D Nguyen, MD MSc · Ocular Imaging Research and Reading Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-10
Primary Completion
2020-04-03
Completion
2021-10-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02931175 on ClinicalTrials.gov